Because the peak age at onset for MS precedes this natural IL-10 decline by one to two decades, it is conceivable that patients with MS may experience this IL-10 trough–and the associated unopposed increase in TNF-α, IP-10, and IL-8–earlier in life. Here, IL10 is linked to myeloid sarcoma.